Vifor Pharma Stock

Vifor Pharma EBIT Margin

Delisted·Dec 22, 2022

The EBIT Margin (Operating Margin) of Vifor Pharma (VIFN.SW) as of Aug 17, 2026 is 23.14 %. In the previous year, EBIT Margin (Operating Margin) was 15.63 % — a change of 48.07% (higher).

EBIT Margin

23.14 %

YoY

48.07%

Last updated:

EBIT Margin (Operating Margin) of Vifor Pharma is 2026 23.14 % . EBIT Margin (Operating Margin) of Vifor Pharma was 2025 15.63 % . It decreases by 48.07% higher compared to the previous year.

For Vifor Pharma, the operating (EBIT) margin of 23.1% is up versus 10.0% a few years ago.

Access this data via the Eulerpool API

Vifor Pharma Stock analysis

What does Vifor Pharma do? Vifor Pharma AG is a leading pharmaceutical company based in St. Gallen, Switzerland. The company has a long history and over 100 years of experience in the manufacturing of pharmaceutical products. It was founded in 1872 as Etablissements Gallois and has undergone various mergers and acquisitions. Today, it is part of the global Galenica Group and has branches in over 30 countries. Vifor Pharma AG focuses on the development and production of medications for the treatment of iron deficiency and kidney diseases. It diversifies its business across different market segments and geographic regions. The company's well-known products include iron preparations sold under different brands such as Ferinject, Injectafer, and Venofer, used for the treatment of iron deficiency anemia in both intravenous and tablet forms. another important business area for Vifor Pharma AG is nephrology, with a wide range of kidney and dialysis products available, including treatments for hyperphosphatemia and anemia in dialysis patients. To strengthen its innovation, the company has invested in partnerships, such as an exclusive license for the distribution of Vadadustat, an oral medication for the treatment of anemia in chronic kidney disease. Vifor Pharma AG has also invested in the digitalization and data-driven technologies, acquiring a stake in the Austrian company medisign GmbH in 2020 to expand its expertise in digital health and telemedicine. In terms of sustainability, the company aims to be carbon-neutral by 2025 and has implemented measures to reduce its CO2 footprint. With its long history, diverse portfolio of products and services, and investments in innovation and sustainability, Vifor Pharma AG is well-positioned for future success. Vifor Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vifor Pharma stock

EBIT Margin (Operating Margin) of Vifor Pharma is 23.14 % in 2026.

EBIT Margin (Operating Margin) of Vifor Pharma changed from 15.63 % to 23.14 %, representing a 48.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Vifor Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Vifor Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

Margins — Vifor Pharma

All Key Metrics — Vifor Pharma